Vmbook Online ordering

Avanir Pharmaceuticals Inc

Avanir Pharmaceuticals, Inc. (AVNR) is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing central nervous system (CNS) therapy products. The company's lead product is NUEDEXTA, which is the first and only FDA-approved treatment for pseudobulbar affect (PBA). PBA is a common, chronic neurological disorder that causes involuntary, sudden, and frequent episodes of laughing and/or crying. NUEDEXTA is available in all 50 states in the U.S. and select countries.

In terms of financials, Avanir Pharmaceuticals reported net revenues of $101.4 million for the fiscal year ended December 31, 2020, representing a 13% increase compared to the previous fiscal year. The company's net income for the same period was $22.4 million, or $0.74 per diluted share, compared to a net loss of $6.4 million, or $0.23 per diluted share, in the previous fiscal year.

As of December 31, 2020, Avanir Pharmaceuticals had cash, cash equivalents, and short-term investments of $216.8 million, compared to $166.9 million as of December 31, 2019.

In terms of growth, Avanir Pharmaceuticals has been focusing on expanding the label and the commercial potential of NUEDEXTA. The company has also been investing in research and development for its pipeline of CNS-focused therapies.

Overall, Avanir Pharmaceuticals has been performing well financially, with increasing revenues and net income. The company's growth is primarily driven by the success of its lead product NUEDEXTA, and it continues to invest in its pipeline of CNS-focused therapies. However, it is important to note that investing in individual stocks, including AVNR, always carries risks and it is recommended to consult with a financial advisor before making any investment decisions.